Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2013

View Archived Issues

Novel potassium channel opener discovered at SciFluor Life Sciences

New genetic biomarker of survival in patients with idiopathic pulmonary fibrosis

A synergistic immunotherapy-mediated approach to target glioma growth

ADC Therapeutics and BZL Biologics enter license and collaboration agreement

Pfizer's tofacitinib citrate now approved in several additional countries

Data on ABT-267 alone and in combination therapy reported at recent conferences

Clinical data presented on Upsher-Smith's drug formulations for epilepsy

Intellipharmaceutics provides updates on Rexista oxycodone technology development

Teva submits IND for RX-3117 for solid tumors

Seattle Genetics begins phase I trial of SGN-CD33A in AML

Furiex completes enrollment in phase III trials of eluxadoline

Dart Therapeutics begins phase Ib/IIa study of HT-100

Biogen presents in vivo and phase I pharmacokinetic results for BIIB-037

Erivedge receives conditional E.U. approval

FDA grants QIDP designation to eravacycline

NCIC Clinical Trials Group to conduct phase II DPX-Survivac study

NeoStem forms regulatory T-cell collaboration with UCSF

Zealand Pharma and Boehringer Ingelheim design new GLP-1 and GL receptor agonists

Achillion Pharmaceuticals presents novel antibacterial agents

Researchers at Redx Pharma prepare novel agents for influenza virus infection

New hVps34 inhibitors disclosed by Millennium Pharmaceuticals

Shin Nippon Biomedical Laboratories and RIKEN execute research agreement

Pfizer synthesizes new sodium channel blockers

Alize Pharma begins first phase I trial of unacylated ghrelin analogue

Ocera Therapeutics and Tranzyme complete merger

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...